Lessons Learned from Target-Based Lead Discovery

Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates

Volumn , Issue , 2009, Pages 99-115

  Gassel, Michael ^a   Cramer, Jörg ^a   Kern, Christopher ^a   Noack, Sandra ^a   Streber, Wolfgang ^a  

^a Intervet Innovation GmbH   (Germany)

Author keywords

Antiinfectives; Antiparasitics; Lead discovery; Screening library; Targets; Veterinary drugs

Indexed keywords

EID: 84883900473     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527626816.ch7     Document Type: Chapter

References (51)

1. Campbell, W.C. (1993) Ivermectin, an antiparasitic agent. Medicinal Research-Reviews, 13, 61-79.
2. Pink, R., Hudson, A., Mouries, M.-A. and Bendig, M. (2005) Opportunities and challenges in antiparasitic drug discovery. Nature Reviews. Drug Discovery, 4, 727-740.
3. Drews, J. (2000) Drug discovery: Ahistorical perspective. Science, 287, 1960-1964.
4. Sams-Dodd, F. (2005) Target-based drug discovery: is something wrong? Drug Discovery Today, 10, 139-147.
5. Booth, B. and Zemmel, R. (2004) Prospects for productivity. Nature Reviews Drug Discovery, 3, 451-456.
6. Sugiyama, Y. (2005) Druggability selecting optimized drug candidates. Drug Discovery Today, 10, 1577-1579.
7. Cheng, A.C., Coleman, R.G., Smyth, K.T., Cao, Q., Soulard, P., Caffrey, D.R., Salzberg, A.C. and Huang, E.S. (2007) Structure-based maximal affinity model predicts small-molecule druggability. Nature Biotechnology, 25, 71-75.
8. Keller, T.H., Pichota, A. and Yin, Z. (2006) A practical view of 'druggability'. Current Opinion in Chemical Biology, 10, 357-361.
9. Wenlock, M.C., Austin, R.P., Barton, P., Davis, A.M. and Leeson, P.D. (2003) A comparison of physicochemical property profiles ofdevelopment and marketed oral drugs. Journal of Medicinal Chemistry, 46, 1250-1256.
10. Frearson, J.A., Wyatt, P.G., Gilbert, I.H. and Fairlamb, A.H. (2007) Target assessment for antiparasitic drug discovery Trends in Parasitology, 23, 589-95.
11. Kennedy, T. (1997) Managing the drug discovery/development interface. Drug Discovery Today, 2, 436-444.
12. Whitebread, S., Hamon, J., Bojanic, D. and Urban, L. (2005) Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discovery Today, 10, 1421-1433.
13. Finlayson, K., Turnbull, L., January, C.T., Sharkey, J. and Kelly, J.S. (2001) [3H] dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. European Journal of Pharmacology, 430, 147-148.
14. Papkovsky, D.B., Hynes, J. and Will, Y. (2006) Respirometric Screening Technology for ADME-Tox studies. Expert Opinion on Drug Metabolism and Toxicology, 2, 313-323.
15. Houck, K.A. and Kavlock, R.J. (2008) Understanding mechanisms of toxicity: insights from drug discovery research. Toxicology and Applied Pharmacology, 227, 163-178.
16. Krejsa, C.M., Horvath, D., Rogalski, S.L., Penzotti, J.E., Mao, B., Barbosa, F. and Migeon, J.C. (2003) Predicting ADME properties and side effects: The BioPrint approach. Current Opinion in Drug Discovery and Development, 6, 70-480.
17. Miculka, C., Meyer, T., Kern, C. and Droux, S. (2008) Zilpaterol enantiomer compositions and methods of making and using such compositions. WO 2008/006828.
18. Clark, D.E. (1999) Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. Journal of Pharmaceutical Sciences, 88, 807-814.
19. Chou, J.T. and Jurs, P. (1979) Computerassisted computation of partition coefficients from molecular structures using fragment constants. Journal of Chemical Information and Computer Sciences, 19, 172-178.
20. Rothacker, B., Werr, M. and Ilg, T. (2008) Succinic semialdehyde dehydrogenase from the parasitic cattle tick Rhipicephalus microplus: Gene identification, biochemical characterization and comparison with the mouse ortholog. Molecular and Biochemical Parasitology, 161, 32-43.
21. Taylor, M.A. (2001) Recent developments in ectoparasiticides. Veterinary Journal, 161, 253-268.
22. Mason, J.S. (2007) Rethinking Similarity & the Chemotype Concept: Using Biological Fingerprints as a More Relevant Descriptor. The conference for Compound Profiling & Chemogenomic Approaches in Philadelphia, USA, October of 2007.
23. Jacoby, E., Schuffenhauer, A., Popov, M., Azzaoui, K., Havill, B., Schopfer, U., Engeloch, C., Stanek, J., Acklin, P., Rigollier, P., Stoll, F., Koch, G., Meier, P., Orain, D., Giger, R., Hinrichs, J., Malagu, K., Zimmermann, J. and Roth, H. (2005) Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection. Current Topics in Medicinal Chemistry, 5, 397-411.
24. Schnur, D.M. (2008) Recent trends in library design: 'Rational design' revisited. Current Opinion in Drug Discovery and Development, 11, 375-380.
25. Gillet, V.J. (2008) New directions in library design and analysis. Current Opinion in Chemical Biology, 12, 372-378.
26. Snowden, M. and Green, D.V.S. (2008) The impact of diversity-based, high-throughput screening on drug discovery: "Chance favours the prepared mind". Current Opinion in Drug Discovery and Development, 11, 553-558.
27. Pereira, D.A. and Williams, J.A. (2007) Origin and evolution of high throughput screening. British Journal of Pharmacology, 152, 53-61.
28. Webb, T.R. (2005) Current directions in the evolution of compound libraries. Current Opinion in Drug Discovery and Development, 8, 303-308.
29. Gorse, A. (2006) Diversity in medicinal chemistry space. Current Topics in Medicinal Chemistry, 6, 3-18.
30. Alper, J. (1994) Drug discovery on the assembly line. Science, 264, 1399-1401.
31. Gorse, A.-D. (2006) Diversity in the medicinal chemistry space Curr. Topics in Medicinal Chemistry, 6, 3-18.
32. Beno, B.R. and Mason, J.S. (2001) The design of combinatorial libraries using properties and 3D pharmacophore fingerprints. Drug Discovery Today, 6, 251-258.
33. Brown, R.D. and Martin, Y.C. (1996) Use of structure activity data to compare structure based clustering methods and descriptors for use in compound selection. Journal of Chemical Information and Computer Sciences, 36, 572-584.
34. Gillet, V.J., Willett, P. and Bradshaw, J. (1997) The effectiveness of reactant pools for the effectiveness of reactant pools for generating structurally diverse combinatorial libraries. Journal of Chemical Information and Computer Sciences, 37, 731-740.
35. Martin, Y.C. (2001) Diverse viewpoints on computational aspects of molecular diversity. Journal of Combinatorial Chemistry, 3, 231-50.
36. Bajorath, J. (2002) Integration of virtual and high-throughput screening. Nature Reviews. Drug Discovery, 1, 882-894.
37. Lipinski, C., Lombardo, F., Dominy, B.W. and Feeney, P.J. (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46, 3-25.
38. Ford, M. (ed.) (2003) Physical and Molecular Properties of Agrochemicals: Insights from an Analysis of Screen Inputs, Hits, Leads and Products, Blackwell Publishing, New York, pp. 51-54.
39. Clarke, E.D. and Delaney, J.S. (2002) EuroQSAR 2002-Designing Drugs and Crop Protectants: Processes, problems and solutions, EURO QSAR 2002, Southampton, UK.
40. Tice, C.M. (2002) Selecting the right compounds for screening: use of surface-area parameters. Pest Management Science, 58, 219-233.
41. Artursson, P., Palm, K. and Luthman, K. (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Advanced Drug Delivery Reviews, 46, 27-43.
42. Cruciani, G., Crivori, P., Carrupt, P.-A. and Testa, B. (2000) Molecular fields in quantitative structure permeation relationships: The VolSurf approach. Journal of Molecular Structure (Theochem), 503, 17-30.
43. Gregori-Puigjane, E. and Mestres, J. (2008) Coverage and bias in chemical library design. Current Opinion in Chemical Biology, 12, 359-365.
44. Cavalli, A., Poluzzi, E., De Ponti, F. and Recanatini, M. (2002) Toward a pharmacophore for drugs inducing long QT syndrome: Insights from a CoMFA study of HERG K + channel blockers. Journal of Medicinal Chemistry, 45, 3844-3853.
45. De Groot, M.J., Ackland, M.J., Horne, V.A., Alex, A.A. and Jones, B.C. (1999) A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. Journal of Medicinal Chemistry, 42, 4062-4070.
46. Pajeva, I.K. and Wiese, M. (2002) Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: Explanation of structural variety (hypothesis). Journal of Medicinal Chemistry, 45, 5671-5686.
47. Muthas, D., Sabnis, Y.A., Lundborg, M. and Karlen, A. (2008) Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls ofpost-filtering. Journal of Molecular Graphics and Modelling, 26, 1237-1251.
48. Schnur, D., Beno, B.R., Good, A. and Tebben, A. (2004) Approaches to target class combinatorial library design. Methods in Molecular Biology (Clifton, N.J.), 275, 355-378.
49. Lipinski, C. Compound storage in DMSO: Synergy between water uptake and cooling and contact sonication as a solution, IQPC Compound Management and Integrity 2005, London, UK.
50. Sofia, M.J., Stevenson, J.M. and Houston, J. (2005) Compound management: integrating chemistry, biology and technology in the modern drug discovery environment. Pharmaceutical Discovery, 2005.
51. Chassaing, C., Berger, M., Heckeroth, A., Ilg, T., Jaeger, M., Kern, C., Schmid, K. and Uphoff, M.J. (2008) Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics. Journal of Medicinal Chemistry, 51, 1111-1114.